1442 ET - Apotex shrugs off concerns over potential U.S. tariffs on generic drugs, pointing to its massive Canadian manufacturing setup as a shield. CEO Jeff Watson says on the earnings call that Apotex benefits from "significant North American manufacturing footprint with the majority of our U.S. farm products produced in Canada," adding that management is actively lobbying trade officials on a "North American onshoring initiative that we share with both the U.S. and Canadian governments." Executive Christine Batur says there is a "unique recognition of Canada as part of the solution," giving the company a "good potential advantage" over global rivals. Apotex is also expanding its U.S. footprint through a new partnership with Halo Pharmaceutical to fund sterile injectable capacity in New Jersey. Shares are down 4.7% to C$35.32.